Mutational landscape of MCPyV-positive and MCPyV-negative merkel cell carcinomas with implications for immunotherapy

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3403-3415

  Goh, Gerald ^a,b   Walradt, Trent ^a   Markarov, Vladimir ^c   Blom, Astrid ^d   Riaz, Nadeem ^c,e   Doumani, Ryan ^d   Stafstrom, Krista ^d   Moshiri, Ata ^d   Yelistratova, Lola ^d   Levinsohn, Jonathan ^a   Chan, Timothy A ^c   Nghiem, Paul ^d,e,f   Lifton, Richard P ^a,b   Choi, Jaehyuk ^a,g,h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g NONE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer genetics; Merkel cell carcinoma; Merkel cell polyomavirus; TP53; Tumor neoantigens

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; K RAS PROTEIN; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH2; PROTEIN P53; MESSENGER RNA; TUMOR MARKER;

ARTICLE; ASXL1 GENE; ATM GENE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; EXOME; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENOME ANALYSIS; HUMAN; MAP3K1 GENE; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MLL2 GENE; MLL3 GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MSH2 GENE; NOTCH1 GENE; NOTCH2 GENE; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; PIK3CA GENE; PTEN GENE; RB1 GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; TRAF7 GENE; TSC1 GENE; TUMOR SUPPRESSOR GENE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; VIROLOGY; VIRUS INFECTION;

BIOMARKERS, TUMOR; CARCINOMA, MERKEL CELL; EXOME; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; MERKEL CELL POLYOMAVIRUS; MUTATION; ONCOGENES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR VIRUS INFECTIONS;

EID: 84962250533     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6494     Document Type: Article

References (41)

1. Hodgson NC. Merkel cell carcinoma: changing incidence trends. Journal of surgical oncology. 2005; 89:1-4.
2. Feng H, Shuda M, Chang Y and Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319:1096-1100.
3. Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu YM, Dhanasekaran SM, Palanisamy N, Siddiqui J, Cao X, Su F, Wang R, Xiao H, Kunju LP, et al. The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer research. 2015.
4. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES and Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505:495-501.
5. Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler M and Becker JC. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PloS one. 2012; 7:e31255.
6. Lill C, Schneider S, Item CB, Loewe R, Houben R, Halbauer D, Heiduschka G, Brunner M and Thurnher D. P53 mutation is a rare event in Merkel cell carcinoma of the head and neck. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies. 2011; 268:1639-1646.
7. Ma JE and Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers. 2014; 6:1328-1350.
8. Paulson KG, Carter JJ, Johnson LG, Cahill KW, Iyer JG, Schrama D, Becker JC, Madeleine MM, Nghiem P and Galloway DA. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer research. 2010; 70:8388-8397.
9. Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, Pietromonaco S, Sokil M, Warton EM, Asgari MM and Nghiem P. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. American journal of clinical pathology. 2014; 142:452-458.
10. Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, Jalkanen S and Joensuu H. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a populationbased study. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:2872-2881.
11. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339:1546-1558.
12. Muller PA and Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer cell. 2014; 25:304-317.
13. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499:214-218.
14. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T and Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. Journal of the National Cancer Institute. 2009; 101:938-945.
15. Stransky N, EgloffAM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333:1157-1160.
16. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in Notch1. Science. 2011; 333:1154-1157.
17. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500:415-421.
18. Cancer Genome Atlas Network. Electronic address imo and Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161:1681-1696.
19. Schwarz T and Beissert S. Milestones in photoimmunology. The Journal of investigative dermatology. 2013; 133:E7-E10.
20. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS and Chang Y. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:16272-16277.
21. Demetriou SK, Ona-Vu K, Sullivan EM, Dong TK, Hsu SW and Oh DH. Defective DNA repair and cell cycle arrest in cells expressing Merkel cell polyomavirus T antigen. International journal of cancer Journal international du cancer. 2012; 131:1818-1827.
22. Schrama D, Hesbacher S, Becker JC and Houben R. Survivin downregulation is not required for T antigen knockdown mediated cell growth inhibition in MCV infected merkel cell carcinoma cells. International journal of cancer Journal international du cancer. 2013; 132:2980-2982.
23. Kwun HJ, Shuda M, Feng H, Camacho CJ, Moore PS and Chang Y. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell host & microbe. 2013; 14:125-135.
24. Shuda M, Kwun HJ, Feng H, Chang Y and Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. The Journal of clinical investigation. 2011; 121:3623-3634.
25. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL and Roberts TM. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell. 1990; 60:167-176.
26. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524:47-53.
27. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M and Moll UM. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015; 523:352-356.
28. Li D, Marchenko ND and Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011; 18:1904-1913.
29. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X and Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. 2013; 32:599-609.
30. Sidera K and Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent patents on anti-cancer drug discovery. 2014; 9:1-20.
31. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC and McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast cancer research and treatment. 1993; 26:225-235.
32. Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC, Wu L and Sidransky D. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. Journal of the National Cancer Institute. 2003; 95:961-970.
33. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014; 371:2189-2199.
34. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348:124-128.
35. Liu C, Yang X, Duffy B, Mohanakumar T, Mitra RD, Zody MC and Pfeifer JD. ATHLATES: accurate typing of human leukocyte antigen through exome sequencing. Nucleic acids research. 2013; 41:e142.
36. Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, Thor Straten P, Nghiem P, Becker JC and Hadrup SR. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:1768-1778.
37. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, TordoffJ, Carlson K, Overton JD, Liu KJ, et al. Genomic landscape of cutaneous T cell lymphoma. Nature genetics. 2015; 47:1011-1019.
38. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333-339.
39. Amarasinghe KC, Li J, Hunter SM, Ryland GL, Cowin PA, Campbell IG and Halgamuge SK. Inferring copy number and genotype in tumour exome data. BMC genomics. 2014; 15:732.
40. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology. 2011; 12:R41.
41. Paulson KG, Lemos BD, Feng B, Jaimes N, Penas PF, Bi X, Maher E, Cohen L, Leonard JH, Granter SR, Chin L and Nghiem P. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. The Journal of investigative dermatology. 2009; 129:1547-1555.